// App-Quantinova.ai

1080 : A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC).

Researchers

Presenter

  • Sara M. Tolaney

Principal Investigators

  • David R. Ziehr

  • Hao Guo

  • Beth Overmoyer

  • Rakesh K. Jain

  • Dan G. Duda

  • Steven J. Isakoff

  • Jane E. Brock

  • Elena Ivanova

  • Cloud Paweletz

  • Michelle Demeo

  • Nikhil H. Ramaiya

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MAMassachusetts General Hospital, Boston, MADana-Farber Cancer Institute, Boston, MA

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Mater Misericordiae University Hospital, Mmuh, Ireland

  • Harvard Medical School, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved